Abattis Bioceuticals Corp (OTCMKTS:ATTBF) provided a comprehensive operational and corporate update regarding its recent developments.
Abattis reports strong quarter despite not trading on CSE
With the company still undergoing a review process by the British Columbia Securities Exchange Commission, its listing on the Canadian Stock exchange will remain halted. Since August 8, 2019, Abattis has worked with the BCSC by providing responses to its requests. Having met continuous disclosure requirement the company is currently is in a better position and expects the commission to finalize the review to recommence trading.
Regardless of the halt in trading of its stock, Abattis has taken measures to enhance its position like closure of non-profitable divisions and focusing on acquisitions with potential. The company is about to wind up a cannabis developing, testing and therapeutic distribution firm in North America. It recently closed a $25 million equity line deal with Dutchess Opportunity Fund. Abattis will file a registration statement for its shares with the US SEC issued to Dutchess under the deal.
New product sales through Pro Natura boosting revenue
The company has been growing its revenue which is attributable to the success of Pro Natura B.V, which is a European based nutraceutical company. The Pro Natura acquisition last year helped it boost sales for the fiscal year ended September 30, 2019. Abattis is focused on enhancing stockholder value as well as organic growth of the business through the implementation of strategies optimizing operations and increasing revenues.
Most importantly, the growth in sales has been due to the launch of new products that included a collection of CBD oils and new women’s product lines that include vegan proteins and collagen. The European affiliate witnessed positive responses for the launched product lines, and is planning to introduce new products to boost profit margins going forward.
One of the company’s products that have generated more sales through the Pro Natura affiliate is Comfort. Launched in 2018, Comfort, is neutraceutical that activates endocannabinoid system and nourishes endorphin release during pain. With the success Comfort has enjoyed in Europe the company plans to launch Comfort Extra Strength.
Post Views: 40,691 Can you spot the difference between the hemp plant and marijuana plant? Hint: It’s not in the...
Stem Holdings Inc (OTCMKTS:STMH) Reports A Growth Of 960% In Q3 2020: Unveils TJGardens Branded Tinctures
Post Views: 828 Stem Holdings Inc (OTCMKTS:STMH) posted an increase of 960% YoY to $6.7 million in Q3 2020. It...
Indiva Ltd (OTCMKTS:NDVAF) Signs Three Provincial Agreements: Expands Distribution Network To Eight Provinces: Reports A Robust Growth Of 1273.7% In Q2 2020 Revenues
Post Views: 732 Indiva Ltd (OTCMKTS:NDVAF) posted a robust growth of 1273.7% YoY to CAD 2.826 million in revenues in...
4Front Ventures Corp (OTCMKTS:FFNTF) Receives Approval From CCC For Mission Dispensary and Cultivation Facilities In Worcester: Will Commence Adult-Use Cannabis Sales
Post Views: 779 CCC (Cannabis Control Commission) in Massachusetts approved cultivation and processing facilities and Mission Dispensary of 4Front Ventures...
Pure Sunfarms, A Joint Venture Of Village Farms International Inc (NASDAQ:VFF), Ships Bottled Oil Products TO British Columbia
Post Views: 856 Pure Sunfarms, which is a Village Farms International Inc (NASDAQ:VFF) JV, commenced shipment of Cannabis 2.0 products...
Health Canada Grants Cannabis 2.0 License To Abba Medix Corp, An Auxiliary Of Canada House Cannabis Group Inc (OTCMKTS:SARSF)
Post Views: 705 Abba Medix Corp., a wholly-owned subsidiary of Canada House Cannabis Group Inc (OTCMKTS:SARSF), received an amended cannabis...